NCT03741530View on ClinicalTrials.gov

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

NACompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 15, 2018

Primary Completion Date

September 23, 2020

Study Completion Date

September 23, 2020

Conditions
Intracerebral Hemorrhage
Interventions
DRUG

Glibenclamide Tablets

Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.

OTHER

Standard management for ICH

Usual care and drug in hospital

Trial Locations (5)

710032

Xijing Hospital, Xi'an

710038

Tangdu Hospital, Xi'an

712000

Xianyang Central Hospital, Xianyang

723000

Hanzhong Central Hospital, Hanzhong

725000

Ankang Central Hospital, Ankang

All Listed Sponsors
lead

Xijing Hospital

OTHER

NCT03741530 - Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter